NCT00981890
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Tyrosine-kinase inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patient must have 1-3 brain metastases; At least one lesion must have a maximum diameter greater than or equal to 4.0 cm in any direction; If multiple lesions are present and one lesion is at the maximum diameter, the other(s) must not exceed 3cm
Exclusions: Patients with leptomeningeal metastases; Patients with metastases in the brainstem or within 5 mm of the optic chiasm or optic nerve; Patients with prior resection (surgery) of cerebral metastasis
https://ClinicalTrials.gov/show/NCT00981890